Photocure ASA - Company Profile
Powered by 
All the sales intelligence you need on Photocure ASA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Photocure ASA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Photocure ASA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Photocure ASA (Photocure) is a specialty pharmaceutical company focused on delivering transformative solutions for bladder cancer patients. It develops and markets pharmaceuticals for the diagnosis and treatment of bladder cancer and precancerous conditions based on its photodynamic technology. It manufactures and commercializes medical products aimed at improving cancer detection and treatment outcomes. Its major product is offered under the brand names Hexvix/Cysview, which is used for the detection and resection of non-muscle invasive bladder cancer. Photocure's products are primarily utilized by healthcare providers in the uro-oncology segment to enhance patient care and reduce disease recurrence. The company sells products directly through its own specialty and medical teams in the US and Nordic and through partnerships with Juno Pharmaceuticals and BioSyent Pharma.in Canada and Australia, and New Zealand. Photocure is headquartered in Oslo, Norway.
Headquarters
Norway
Address
Hoffsveien 4, Oslo, 0275
Website
www.photocure.com
Telephone
47 2 2062210
No of Employees
101
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PHO (OSL)
Revenue (2024)
$51.3M
1.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
54.5%
(2024 vs 2023)
Market Cap*
$161.1M
Net Profit Margin (2024)
XYZ
54.7%
(2024 vs 2023)
* As of and is in US$
Photocure ASA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Detection and Diagnosis of Bladder Cancer | Hexvix |
| Hexaminolevulinate (85mg) | Cysview |
| Hexaminolevulinate (HCL) | Cevira |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In June, the company acquired Vesica Health. |
| 2026 | Regulatory Approval | In March, the company received approval from the Drug Registration Certificate from China’s National Medical Products Administration (NMPA), to enable the launch of its products in China. |
| 2025 | Contracts/Agreements | In October, the company partnered with Intelligent Scopes Corporation, on the development of artificial intelligence for blue light cystoscopy. |
Competitor Comparison
| Key Parameters | Photocure ASA | Chiesi Ltd | Medistim ASA | Navamedic ASA | Biofrontera AG |
|---|---|---|---|---|---|
| Headquarters | Norway | United Kingdom | Norway | Norway | Germany |
| City | Oslo | Manchester | Oslo | Oslo | Leverkusen |
| State/Province | - | England | - | - | Nordrhein-Westfalen |
| No. of Employees | 101 | 387 | 159 | 40 | 82 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dylan Hallerberg | Chairman | Executive Board | 2023 | - |
| Daniel Schneider | President; Chief Financial Officer - Acting; Chief Executive Officer | Senior Management | 2026 | - |
| Anders Neijber | Chief Medical Officer - Global Medical Affairs and Clinical Development and R&D | Senior Management | 2022 | - |
| Jane Healy | Vice President; General Manager - EMEA | Senior Management | 2025 | - |
| Anja Gossens-Von Der Heidt | Head - Global Human Resources | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer